Gedeon Richter Acquires Celmatix’s Discovery Portfolio
We are proud to share that Gedeon Richter has acquired Celmatix Therapeutics’ women’s health discovery portfolio, including our programs spanning infertility, endometriosis, and ovarian aging. The portfolio includes a first-in-class oral FSH receptor agonist, a novel JNK inhibitor for endometriosis, and early-stage AMH-targeting antibodies designed to expand control over ovarian folliculogenesis.
Read the full announcement
Press Releases
Summary Block
This block is invalid. Please check the block settings and try again.
Donec id justo non metus auctor commodo ut quis enim. Mauris fringilla dolor vel condimentum imperdiet.